Compound Heterozygous DARS2 Mutations as a Mimic of Hereditary Spastic Paraplegia

Martje G. Pauly; Yorck Hellenbroich; Kathrin Grundmann-Hauser; Frauke Hinrichs; Katja Lohmann; Norbert Brüggemann

doi:10.1002/mdc3.13258

Compound Heterozygous DARS2 Mutations as a Mimic of Hereditary Spastic Paraplegia

Martje G. Pauly, Yorck Hellenbroich, Kathrin Grundmann-Hauser, Frauke Hinrichs, Katja Lohmann, Norbert Brüggemann^*

^*Korrespondierende/r Autor/-in für diese Arbeit

Eberhard Karls Universität Tübingen

3 Zitate (Scopus)

Originalsprache	Englisch
Zeitschrift	Movement Disorders Clinical Practice
Jahrgang	8
Ausgabenummer	6
Seiten (von - bis)	972-976
Seitenumfang	5
DOIs	https://doi.org/10.1002/mdc3.13258
Publikationsstatus	Veröffentlicht - 08.2021

Fördermittel

The study was supported by the German Research Foundation (FOR2488), the German Research Foundation via the Clinician Scientist School Lübeck (DFG‐GEPRIS 413535489), and the Damp Foundation. The authors do not declare any conflicts of interest or competing interests. Martje G. Pauly is funded by the Clinician Scientist School Lübeck. Yorck Hellenbroich has nothing to report. Kathrin Grundmann‐Hauser has nothing to report. Frauke Hinrichs has nothing to report. Katja Lohmann received research funding from the German Research Foundation, the Damp‐Stiftung and the Movement Disorders Society and is member of the GP2 initiative within ASAP ( https://parkinsonsroadmap.org/gp2/ ). Norbert Brüggemann served as a consultant for Censa Pharmaceuticals, Centogene, and Bridgebio and is funded by the German Research Foundation (BR4328.2‐1, GRK1957).

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Dokumente

10.1002/mdc3.13258

Weitere Links

Zitieren

@article{e595d0077380477ab07fd7b2aa534e4a,

title = "Compound Heterozygous DARS2 Mutations as a Mimic of Hereditary Spastic Paraplegia",

author = "Pauly, \{Martje G.\} and Yorck Hellenbroich and Kathrin Grundmann-Hauser and Frauke Hinrichs and Katja Lohmann and Norbert Br{\"u}ggemann",

note = "Funding Information: The study was supported by the German Research Foundation (FOR2488), the German Research Foundation via the Clinician Scientist School L{\"u}beck (DFG‐GEPRIS 413535489), and the Damp Foundation. The authors do not declare any conflicts of interest or competing interests. Funding Information: Martje G. Pauly is funded by the Clinician Scientist School L{\"u}beck. Yorck Hellenbroich has nothing to report. Kathrin Grundmann‐Hauser has nothing to report. Frauke Hinrichs has nothing to report. Katja Lohmann received research funding from the German Research Foundation, the Damp‐Stiftung and the Movement Disorders Society and is member of the GP2 initiative within ASAP ( https://parkinsonsroadmap.org/gp2/ ). Norbert Br{\"u}ggemann served as a consultant for Censa Pharmaceuticals, Centogene, and Bridgebio and is funded by the German Research Foundation (BR4328.2‐1, GRK1957).",

year = "2021",

month = aug,

doi = "10.1002/mdc3.13258",

language = "English",

volume = "8",

pages = "972--976",

journal = "Movement Disorders Clinical Practice",

issn = "2330-1619",

publisher = "John Wiley and Sons Ltd",

number = "6",

}

TY - JOUR

T1 - Compound Heterozygous DARS2 Mutations as a Mimic of Hereditary Spastic Paraplegia

AU - Pauly, Martje G.

AU - Hellenbroich, Yorck

AU - Grundmann-Hauser, Kathrin

AU - Hinrichs, Frauke

AU - Lohmann, Katja

AU - Brüggemann, Norbert

N1 - Funding Information: The study was supported by the German Research Foundation (FOR2488), the German Research Foundation via the Clinician Scientist School Lübeck (DFG‐GEPRIS 413535489), and the Damp Foundation. The authors do not declare any conflicts of interest or competing interests. Funding Information: Martje G. Pauly is funded by the Clinician Scientist School Lübeck. Yorck Hellenbroich has nothing to report. Kathrin Grundmann‐Hauser has nothing to report. Frauke Hinrichs has nothing to report. Katja Lohmann received research funding from the German Research Foundation, the Damp‐Stiftung and the Movement Disorders Society and is member of the GP2 initiative within ASAP ( https://parkinsonsroadmap.org/gp2/ ). Norbert Brüggemann served as a consultant for Censa Pharmaceuticals, Centogene, and Bridgebio and is funded by the German Research Foundation (BR4328.2‐1, GRK1957).

PY - 2021/8

Y1 - 2021/8

UR - https://www.scopus.com/pages/publications/85107785768

UR - https://www.mendeley.com/catalogue/4a2df11e-24f6-3c98-97bd-02a8bda28433/

U2 - 10.1002/mdc3.13258

DO - 10.1002/mdc3.13258

M3 - Journal articles

C2 - 34405109

AN - SCOPUS:85107785768

SN - 2330-1619

VL - 8

SP - 972

EP - 976

JO - Movement Disorders Clinical Practice

JF - Movement Disorders Clinical Practice

IS - 6

ER -